吉格列汀(rINN)以前被鑒定為LC15-0444，是新型二肽基肽酶-4(DPP-4)抑制劑類藥物的口服抗高血糖劑(抗糖尿病藥物)。眾所周知，DPP-4抑制劑的降糖作用主要由GLP-1和胃抑制多肽(GIP)內(nèi)分泌激素介導(dǎo)，而胃抑制多肽(GIP)內(nèi)分泌激素被DPP-4失活。
tert-Butyl 3,3-difluoropiperidine-1-carboxylate
2,4-Bis(trifluoromethyl)-5,6,7,8-tetrahydropyrido-[3,4-d]pyrimidine hydrochloride
7-Boc-2,4-bis(trifluoromethyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine
tert-Butyl 3-oxo-4-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate
